Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Phase 2a Study to Assess Safety & Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain

13. april 2020 opdateret af: TheraVasc Inc.

A Randomized, Double-blinded, Phase 2a Study to Assess the Safety and Pharmacokinetics of a Sustained Release Formulation of Sodium Nitrite (TV1001sr) in Patients With Diabetic Neuropathic Pain (DNP)

In this study, subjects with diabetic neuropathic pain (DNP) will be treated for 12 weeks with either placebo, 40 or 80 mg sustained release sodium nitrite (TV1001sr) twice daily. Primary endpoints will be safety and pharmacokinetics. Assessment of the study medications affects on pain following treatment will also be recorded.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a dose-ranging study to evaluate the safety, pharmacokinetics, and tolerability of multiple doses of an oral, sustained release formulation of sodium nitrite (TV1001sr) in subjects with DNP. The primary objective is to assess the safety and tolerability of multiple doses of twice daily 40 mg and 80 mg TV1001sr compared with placebo over a 12 week treatment period and the pharmacokinetics of the sustained release formulation of sodium nitrite. Secondary objectives are to evaluate the pharmacokinetics and markers of functional improvement including pain questionnaires, quantitative sensory testing and changes in markers of diabetes.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

26

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • Ohio
      • Centerville, Ohio, Forenede Stater, 45458
        • Ohio Pain Clinic

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Female subjects must be post-menopausal, sterilized or using suitable birth control
  • Diagnosis of diabetes (HbA1c > 6.0)
  • Diagnosis of diabetic peripheral neuropathy pain in feet
  • Presence of ongoing diabetic neuropathic for at least 3 months
  • A pain score of greater than or equal to 4 on the Numerical Pain Rating Scale at screening
  • Ability to provide written informed consent

Exclusion Criteria:

  • Patients with fibromyalgia or regional pain caused by lumbar or cervical compression
  • History or diagnosis of significant neurological disease
  • History and diagnosis of clinically significant psychiatric diseases
  • Serious liver disease
  • Poorly controlled diabetes
  • Hypersensitivity to sodium nitrite or related compounds
  • Life expectancy < 6 months
  • A chronic illness that may increase the risks associated with this study
  • Active malignancy requiring active anti-neoplastic therapy that will, in the opinion of the investigator, interfere with study treatment or participation
  • Pregnant or nursing women
  • Current diagnosis of alcohol or other substance abuse
  • Current use of sildenafil or other phosphodiesterase Type 5 Inhibitors
  • History of methemoglobinemia, (met-Hb ≥ 15%)
  • Subject is involved in litigation or receives worker's compensation
  • Inability to speak English

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo
One placebo tablet administered twice daily for 12 weeks.
Medicin: Placebo
Placebo tablets containing same excipients and coatings used in the active tablets, without sodium nitrite being added.
Aktiv komparator: 40 mg TV1001sr
One 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
Medicin: Sodium nitrite
Sustained release formulation of sodium nitrite
Andre navne:
  • TV1001sr
Placebo komparator: Placebo (2)
Two placebo tablets administered twice daily for 12 weeks.
Medicin: Placebo
Placebo tablets containing same excipients and coatings used in the active tablets, without sodium nitrite being added.
Aktiv komparator: 80 mg TV1001sr
Two 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
Medicin: Sodium nitrite
Sustained release formulation of sodium nitrite
Andre navne:
  • TV1001sr

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Reporting of Adverse Events During 12 Week Study Period
Tidsramme: 12 weeks
The primary objective of this clinical study is to evaluate the safety and tolerability of multiple doses of twice daily 40mg and 80mg sustained release sodium nitrite compared with placebo over a 12 week treatment period. The following safety parameters will also be assessed: concomitant medication usage, physical examination, vital signs, Comprehensive Metabolic Panel, and complete blood count. Assessment of acute adverse events (i.e., drop in blood pressure, dizziness) after administration of each dose level. Counts are number of subjects reporting at least 1 Adverse Event. The total Adverse Events recorded in each cohort is also reported.
12 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Pharmacokinetics (Blood Levels of Nitrite)
Tidsramme: 1 day
Blood levels of nitrite will be assessed for 6 hours post-administration on the initial dosing visit.
1 day
The Number of Participants Who Reported Use of Analgesic or Medications for Neuropathic Pain.
Tidsramme: 12 weeks
Daily patient reported use of analgesic or medications for neuropathic pain. The use of medications were recorded at the baseline visit and during both the intermediate and final visit for each subject. All subjects used at least one prescription pain medication, other than one subject in the 80-mg dose cohort who used only ibuprofen to control pain. Most subjects used more than one prescription pain medication. There was no change in use of pain medications during the trial period.
12 weeks
Assessment of Patients Reported Pain Through Composite Analysis of Pain Questionaires.
Tidsramme: Baseline (visit 1) and 12 weeks (visit 3)
Subjects completed the Brief pain inventory (BPI), RAND 36 questionnaire, neuropathic pain symptom inventory (NPSI) and Short Form McGill Pain Questionnaire at each visit for these self-reported questionnaires. The BPI is a questionnaire that measures the patient's subjective perception of pain, its exacerbating and alleviating factors, and perceived effect on functional status; the NPSI is a questionnaire that measures the symptoms associated with neuropathic pain; the Short Form McGill Questionnaire subjectively assesses the patients perception of pain described by commonly used adjectives associated with pain. NPSI is average of 12 questions, range from 0 (no pain) to 120 (maximal pain); For BPI severity and interference, questions are scored from 0-10, then there average score for each subsection is calculated (the higher the score, the worse the response); Scores on McGill range from 0-10, lower associated for less pain, then averaged for each sub score and total score.
Baseline (visit 1) and 12 weeks (visit 3)
Clinical Assessment of Pain. (Quantitative Sensory Testing)
Tidsramme: 12 weeks
Quantitative sensory testing (QST) was conducted at each visit to determine patients sensitivity to pain. QST was assessed using a quantitative nerve conductance machine where nerves in the distal extremity are subjected to electrical stimulation to determine the sensory threshold of the skin. Nerve conductance measures how fast an electrical impulse moves through the nerve, and nerve velocity measures the speed at which an electrical impulse moves down a neuronal pathway.
12 weeks
Assessment of Diabetes. (HbA1C Levels)
Tidsramme: 12 weeks
HbA1C levels will be monitored at each visit to determine whether treatment reduces circulating glucose levels.
12 weeks
Assessment of Blood Oxygenation. (Pulse Oximetry)
Tidsramme: 12 weeks
Pulse oximetry will be used at each visit to determine whether treatment improves oxygen levels in the blood.
12 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

TheraVasc Inc.

Samarbejdspartnere

Kettering Health Network

Efterforskere

  • Ledende efterforsker: Amol Soin, PhD, Ohio Pain Clinic

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

28. april 2015

Primær færdiggørelse (Faktiske)

7. december 2015

Studieafslutning (Faktiske)

3. april 2017

Datoer for studieregistrering

Først indsendt

1. april 2015

Først indsendt, der opfyldte QC-kriterier

8. april 2015

Først opslået (Skøn)

9. april 2015

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

24. april 2020

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. april 2020

Sidst verificeret

1. april 2020

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • TheraVasc-TV1001-003

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

Ingen

IPD-planbeskrivelse

IPD will only be available to the PI of the trial, summary information will be published and shared with other researchers.

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Placebo

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Guinea

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner